An update on lipid-based nanodrug delivery systems for leishmaniasis treatment

References

• 1. de Santana NS, de Oliveira de Siqueira LB, do Nascimento T et al. Nanoparticles for the treatment of visceral leishmaniasis: review. J. Nanoparticle Res. 25(2), 24 (2023).
  CASGoogle Scholar
• 2. Mishra DK, Shandilya R, Mishra PK. Lipid based nanocarriers: a translational perspective. Nanomedicine 14(7), 2023–2050 (2018).
  Medline CASGoogle Scholar
• 3. Baharvandi Z, Salimi A, Arjmand R et al. Evaluation of the efficacy of amphotericin B and terbinafine microemulsions and their combination on cutaneous leishmaniasis and comparison with the conventional drug form in BALB/c mice. AAPS PharmSciTech 23(7), 280 (2022).
  Medline CASGoogle Scholar
• 4. Kammona O, Tsanaktsidou E. Nanotechnology-aided diagnosis, treatment and prevention of leishmaniasis. Int. J. Pharm. 605, 120761 (2021).
  Medline CASGoogle Scholar
• 5. de Souza A, Yukuyama MN, Barbosa EJ et al. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids Surf. B. Biointerfaces 193(9), 111097 (2020).
  Medline CASGoogle Scholar
• 6. Khan AU, Jamshaid H, ud Din F et al. Designing, optimization and characterization of trifluralin transfersomal gel to passively target cutaneous leishmaniasis. J. Pharm. Sci. 111(6), 1798–1811 (2022).
  Medline CASGoogle Scholar
• 7. Ferreira MA, de Almeida Júnior RF, Onofre TS et al. Annatto oil loaded nanostructured lipid carriers: a potential new treatment for cutaneous leishmaniasis. Pharmaceutics 13(11), 1912 (2021).
  Medline CASGoogle Scholar
• 8. Mansur-Alves I, Lima BLF, Santos TT et al. Cholesterol improves stability of amphotericin B nanoemulsion: promising use in the treatment of cutaneous leishmaniasis. Nanomedicine (Lond.) 17(18), 1237–1251 (2022).
  CASGoogle Scholar
• 9. Parvez S, Yadagiri G, Arora K et al. Coalition of biological agent (melatonin) with chemotherapeutic agent (amphotericin B) for combating visceral leishmaniasis via oral administration of modified solid lipid nanoparticles. ACS Biomater. Sci. Eng. 9(6), 2902–2910 (2023).
  Medline CASGoogle Scholar
• 10. Anjum A, Shabbir K, Din FU et al. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of cutaneous leishmaniasis. Drug Deliv. 30(1), 2173335 (2023).
  MedlineGoogle Scholar
• 11. Van Bocxlaer K, Gaukel E, Hauser D et al. Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles. Antimicrob. Agents Chemother. 62(5), e02419–17 (2018).
  Medline CASGoogle Scholar
• 12. Salim MW, Shabbir K, ud-Din F et al. Preparation, in-vitro and in-vivo evaluation of rifampicin and vancomycin co-loaded transfersomal gel for the treatment of cutaneous leishmaniasis. J. Drug Deliv. Sci. Technol. 60, 101996 (2020).
  CASGoogle Scholar
• 13. Das SS, Dubey AK, Verma PRP et al. Therapeutic potential of quercetin-loaded nanoemulsion against experimental visceral leishmaniasis: in vitro/ex vivo studies and mechanistic insights. Mol. Pharm. 19(9), 3367–3384 (2022).
  Medline CASGoogle Scholar
• 14. Coelho LD, Souza MMD, Cassali GD et al. Emetic tartar-loaded liposomes as a new strategy for leishmaniasis treatment. Pharmaceutics 15(3), 904 (2023).
  Medline CASGoogle Scholar
• 15. Singh A, Yadagiri G, Negi M et al. Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system. Int. J. Biol. Macromol. 204, 373–385 (2022).
  Medline CASGoogle Scholar